GND 135
Alternative Names: GND-135Latest Information Update: 03 Jul 2024
Price :
$50 *
At a glance
- Originator Gandeeva Therapeutics
- Class Antineoplastics
- Mechanism of Action P97 ATPase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Multiple myeloma
Most Recent Events
- 05 Apr 2024 Preclinical trials in Acute myeloid leukaemia in USA (Intraperitoneal) prior to April 2024
- 05 Apr 2024 Preclinical trials in Multiple myeloma in USA (Intraperitoneal) prior to April 2024
- 05 Apr 2024 Pharmacodynamics and pharmacokinetic data from preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)